At the news
? BEARISHIMPACT 6/10 8-K filed May 7, 2026 at 09:09 ET
Palvella Therapeutics reported Q1 2026 EPS of -$1.20, missing consensus of -$0.93 by 29%, as R&D and G&A expenses rose sharply. Despite the miss, the company highlighted strong cash of $261.9M and reiterated NDA submission for QTORIN rapamycin in microcystic LMs in 2H 2026, with potential approval and launch in 1H 2027.
- Q1 2026 EPS of -$1.20 missed consensus of -$0.93 (29% miss)
- Net loss of $15.8M vs $8.2M in Q1 2025, driven by higher R&D and G&A costs
- Cash, cash equivalents and short-term investments of $261.9M as of March 31, 2026
- NDA submission for QTORIN rapamycin in microcystic LMs on track for 2H 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access